Gleevec is indicated for the treatment of newly diagnosed adult patients with Philadelphia

chromosome–positive (Ph+) chronic myeloid leukemia (CML). Follow-up is limited. Gleevec is

also indicated for the treatment of patients with Ph+ CML in blast crisis, accelerated phase, or in

chronic phase after failure of interferon-alpha therapy. Gleevec is also indicated for the treatment of pediatric patients with Ph+ CML whose disease has recurred after stem cell transplant or who are resistant to interferon alpha therapy. There are no controlled trials demonstrating a clinical benefit, such as improvement in disease-related symptoms or increased survival, in patients with CML in blast crisis, accelerated phase, or chronic phase after failure of interferon-alpha therapy.